Home > Drugs A – Z > Efavirenz/Emtricitabine/Tenofovir (By...

Efavirenz/Emtricitabine/Tenofovir (By mouth)

Treats HIV infection. HIV causes AIDS. This medicine does not cure HIV or AIDS, but combinations of drugs may slow the progress of the disease.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Efavirenz, emtricitabine, and tenofovir combination is used alone or with other anti-HIV medicines to treat human immunodeficiency virus (HIV) infection. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). This medicine does not cure or prevent HIV or AIDS. It helps keep HIV from reproducing and appears to slow down the destruction of the immune system. This may help delay… Read more
Brand names include
Atripla
Drug classes About this
Antiretroviral Agent

What works? Research summarized

Evidence reviews

Addendum to Commission A12-02 (Rilpivirine / Emtricitabine / Tenofovir) [Internet]

The aim of this report was to assess the added benefit of the fixed-dose combination rilpivirine / emtricitabine / tenofovir compared to the appropriate comparator therapy (ACT) (efavirenz in combination with emtricitabine / tenofovir) in the approved therapeutic indication (human immunodeficiency virus type 1 [HIV-1] infection in antiretroviral-naïve adult patients with a viral load of ≤ 100,000 HIV-1 RNA copies/mL).

Rilpivirine / emtricitabine / tenofovir -- Benefit Assessment According to §35a Social Code Book V [Internet]

The aim of this report was to assess the added benefit of the fixed-dose combination rilpivirine / emtricitabine / tenofovir disoproxil (RIL / EMTRI / TENO) compared to the appropriate comparator therapy (ACT) (efavirenz in combination with emtricitabine / tenofovir) in the approved therapeutic indication (human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/mL).

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (EVG/COBI/FTC/TAF) (Genvoya) Fixed-Dose Combination, Oral Tablet) [Internet]

The objective of this systematic review is to evaluate of the beneficial and harmful effects of the fixed-dose combination (FDC) of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/COBI/FTC/TAF) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients 12 years of age and older with no known mutations associated with resistance to the individual components of EVG/COBI/FTC/TAF.

See all (16)

Summaries for consumers

Rilpivirine (Edurant, Eviplera) for the treatment of HIV: Initial treatment in adults: Rilpivirine (Eviplera) in a fixed-dose combination with emtricitabine / tenofovir

Patients starting their first HIV treatment are often given efavirenz in combination with two other drugs. Emtricitabine and tenofovir are one of several pairs of drugs that can be used in this way.In early 2012, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of rilpivirine taken in a fixed-dose combination with emtricitabine / tenofovir (trade name: Eviplera), compared with the fixed-dose combination efavirenz plus emtricitabine / tenofovir. Three studies were available to IQWiG.

Emtricitabine / tenofovir alafenamide (Descovy) for HIV: Overview

The fixed combination emtricitabine / tenofovir alafenamide (trade name: Descovy) has been approved in Germany since April 2016 for the treatment of human immunodeficiency virus (HIV) type 1 infection in adults and adolescents over 12 years of age. It is combined with other treatments.

Comparing initial antiretroviral regimens tenofovir or zidovudine as part of three‐drug combinations for treatment of HIV infection

The introduction of highly active antiretroviral therapy (ART) as treatment for HIV infection has greatly improved mortality and morbidity for adults and adolescents living with HIV around the world. Deciding which treatment regimen to begin for first‐line treatment in ART‐naïve patients, however, remains a significant challenge. Two commonly used medications are tenofovir (TDF) and zidovudine (AZT). The purpose of this review was to assess which of these two medications was the best for initial treatment for people living with HIV, and through our search we identified two randomised controlled trials. We did not find any critical difference between the two medications in regards to serious adverse events or virologic response, but did find that TDF is superior to AZT in terms of immunologic response and adherence and more frequent emergence of resistance. However, these two studies are not directly comparable because they used two related different drugs in addition to TDF and AZT. Future studies and recommendations should focus on specific toxicities and tolerability when comparing these two medications.

See all (8)

PubMed Health Blog...

read all...